Literature DB >> 19422829

A novel ELISA reveals high frequencies of BP180-specific IgE production in bullous pemphigoid.

Kelly A N Messingham1, Megan H Noe, Marisa A Chapman, George J Giudice, Janet A Fairley.   

Abstract

Bullous pemphigoid (BP) is a humoral autoimmune disease directed predominantly against the non-collagenous NC16A domain of the BP180 hemidesmosomal protein. Our laboratory has recently shown, using a mouse xenograft model, that passive transfer of IgE autoantibodies from BP sera induces a skin phenotype that recapitulates the early phases of the disease. Herein, we describe the development of a highly specific and sensitive ELISA to detect circulating IgE autoantibodies that recognize BP180-NC16A. Using this assay, we detected NC16A-specific IgE-class autoantibodies in 77% of BP sera. This frequency, which is significantly higher than reported previously, is comparable to that of anti-NC16A IgG autoantibody production. In 3 BP patients monitored over time, the circulating NC16A-specific levels of both IgE and IgG were associated with clinical disease activity; however, patient sera did not always contain high levels of both isotypes. In conclusion, our ELISA provides a highly sensitive and specific tool for the detection of BP180-specific IgE in patient sera. Furthermore, we report that the majority of BP sera contain both IgE and IgG class autoantibodies specific for NC16A and suggest that screening for both isotypes of autoantibodies may provide a better diagnostic value than IgG alone.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19422829      PMCID: PMC2703696          DOI: 10.1016/j.jim.2009.04.013

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  34 in total

1.  Clinical significance of enzyme-linked immunosorbent assay for the detection of circulating anti-BP180 autoantibodies in patients with bullous pemphigoid.

Authors:  Y Amo; T Ohkawa; M Tatsuta; Y Hamada; T Fujimura; K Katsuoka; T Hashimoto
Journal:  J Dermatol Sci       Date:  2001-05       Impact factor: 4.563

2.  Severity and phenotype of bullous pemphigoid relate to autoantibody profile against the NH2- and COOH-terminal regions of the BP180 ectodomain.

Authors:  SilkeC Hofmann; Sybille Thoma-Uszynski; Thomas Hunziker; Philippe Bernard; Corinna Koebnick; Angelika Stauber; Gerold Schuler; Luca Borradori; Michael Hertl
Journal:  J Invest Dermatol       Date:  2002-11       Impact factor: 8.551

3.  BP180 ELISA using bacterial recombinant NC16a protein as a diagnostic and monitoring tool for bullous pemphigoid.

Authors:  Masakazu Kobayashi; Masayuki Amagai; Keiko Kuroda-Kinoshita; Takashi Hashimoto; Yuji Shirakata; Koji Hashimoto; Takeji Nishikawa
Journal:  J Dermatol Sci       Date:  2002-12       Impact factor: 4.563

4.  Evaluation of a BP180-NC16a enzyme-linked immunosorbent assay in the initial diagnosis of bullous pemphigoid.

Authors:  Y Sakuma-Oyama; A M Powell; N Oyama; S Albert; B S Bhogal; M M Black
Journal:  Br J Dermatol       Date:  2004-07       Impact factor: 9.302

5.  Development of an ELISA for the detection of autoantibodies to BP230.

Authors:  Arno Kromminga; Cassian Sitaru; Christine Hagel; Susanne Herzog; Detlef Zillikens
Journal:  Clin Immunol       Date:  2004-04       Impact factor: 3.969

6.  Production of the entire extracellular domain of BP180 (type XVII collagen) by baculovirus expression.

Authors:  Y Hata; Y Fujii; K Tsunoda; M Amagai
Journal:  J Dermatol Sci       Date:  2000-08       Impact factor: 4.563

7.  IgG, IgA and IgE autoantibodies against the ectodomain of BP180 in patients with bullous and cicatricial pemphigoid and linear IgA bullous dermatosis.

Authors:  S Christophoridis; L Büdinger; L Borradori; T Hunziker; H F Merk; M Hertl
Journal:  Br J Dermatol       Date:  2000-08       Impact factor: 9.302

8.  Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid.

Authors:  E Schmidt; K Obe; E B Bröcker; D Zillikens
Journal:  Arch Dermatol       Date:  2000-02

9.  Identification of a potential effector function for IgE autoantibodies in the organ-specific autoimmune disease bullous pemphigoid.

Authors:  Otobia G Dimson; George J Giudice; Chang Ling Fu; Francoise Van den Bergh; Simon J Warren; Marleen M Janson; Janet A Fairley
Journal:  J Invest Dermatol       Date:  2003-05       Impact factor: 8.551

10.  Pathogenicity of IgE in autoimmunity: successful treatment of bullous pemphigoid with omalizumab.

Authors:  Janet A Fairley; Christian L Baum; Debra S Brandt; Kelly A N Messingham
Journal:  J Allergy Clin Immunol       Date:  2009-01-18       Impact factor: 10.793

View more
  24 in total

1.  Pregnant women have increased incidence of IgE autoantibodies reactive with the skin and placental antigen BP180 (type XVII collagen).

Authors:  Megan H Noe; Kelly A N Messingham; Debra S Brandt; Janet I Andrews; Janet A Fairley
Journal:  J Reprod Immunol       Date:  2010-05-14       Impact factor: 4.054

Review 2.  Targeted Therapies for Autoimmune Bullous Diseases: Current Status.

Authors:  Kyle T Amber; Roberto Maglie; Farzan Solimani; Rüdiger Eming; Michael Hertl
Journal:  Drugs       Date:  2018-10       Impact factor: 9.546

Review 3.  Unraveling the significance of IgE autoantibodies in organ-specific autoimmunity: lessons learned from bullous pemphigoid.

Authors:  K A N Messingham; H M Holahan; J A Fairley
Journal:  Immunol Res       Date:  2014-08       Impact factor: 2.829

4.  Eosinophil localization to the basement membrane zone is autoantibody- and complement-dependent in a human cryosection model of bullous pemphigoid.

Authors:  Kelly N Messingham; Jeffrey W Wang; Heather M Holahan; Rupasree Srikantha; Samantha C Aust; Janet A Fairley
Journal:  Exp Dermatol       Date:  2015-11-23       Impact factor: 3.960

5.  Functional characterization of an IgE-class monoclonal antibody specific for the bullous pemphigoid autoantigen, BP180.

Authors:  Kelly A N Messingham; Amber Onoh; Elizabeth M Vanderah; George J Giudice; Janet A Fairley
Journal:  Hybridoma (Larchmt)       Date:  2012-04

6.  [Bullous pemphigoid: a new look at a well-known disease].

Authors:  G Balakirski; H F Merk; M Megahed
Journal:  Hautarzt       Date:  2014-12       Impact factor: 0.751

7.  Demographics and Autoantibody Profiles of Pemphigoid Patients with Underlying Neurologic Diseases.

Authors:  Kelly N Messingham; Adam D Miller; Nandakumar S Narayanan; Samuel J Connell; Janet A Fairley
Journal:  J Invest Dermatol       Date:  2019-03-12       Impact factor: 8.551

8.  Missing the target: characterization of bullous pemphigoid patients who are negative using the BP180 enzyme-linked immunosorbant assay.

Authors:  Janet A Fairley; Matthew Bream; Colleen Fullenkamp; Sergei Syrbu; Mei Chen; Kelly N Messingham
Journal:  J Am Acad Dermatol       Date:  2012-10-18       Impact factor: 11.527

9.  IgG/IgE bullous pemphigoid with CD45 lymphocytic reactivity to dermal blood vessels, nerves and eccrine sweat glands.

Authors:  Ana Maria Abreu-Velez; J Graham Smith; Michael S Howard
Journal:  N Am J Med Sci       Date:  2010-11

10.  Development of an ELISA for sensitive and specific detection of IgA autoantibodies against BP180 in pemphigoid diseases.

Authors:  Kinga Csorba; Sabine Schmidt; Florina Florea; Norito Ishii; Takashi Hashimoto; Michael Hertl; Sarolta Kárpáti; Leena Bruckner-Tuderman; Wataru Nishie; Cassian Sitaru
Journal:  Orphanet J Rare Dis       Date:  2011-05-28       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.